Additional socioeconomic factors and other characteristics of patients with noninfant B-ALL experiencing relapse after frontline COG clinical trials by race and ethnicity
| Characteristics . | Race/ethnicity grouping . | |||||||
|---|---|---|---|---|---|---|---|---|
| Hispanic of all races (N = 452) . | NH White (N = 957) . | NH Black (N = 115) . | NH Asian (N = 52) . | NH Other (N = 16) . | Other/Unknown (N = 123) . | Total (N = 1715) . | P value . | |
| Institution size (based on frontline trial enrollment)∗, n (%) | .001 | |||||||
| Institution size: ≤50 | 55 (12.2) | 183 (19.2) | 27 (23.5) | 9 (17.3) | 2 (12.5) | 20 (16.3) | 296 (17.3) | |
| Institution size: 51-100 | 138 (30.5) | 295 (30.9) | 32 (27.8) | 12 (23.1) | 9 (56.3) | 23 (18.7) | 509 (29.7) | |
| Institution size: 101-200 | 161 (35.6) | 329 (34.5) | 42 (36.5) | 19 (36.5) | 3 (18.8) | 57 (46.3) | 611 (35.7) | |
| Institution size: >200 | 98 (21.7) | 148 (15.5) | 14 (12.2) | 12 (23.1) | 2 (12.5) | 23 (18.7) | 297 (17.3) | |
| Missing | 0 | 2 | 0 | 0 | 0 | 0 | 2 | |
| Treatment site location†, n (%) | <.0001 | |||||||
| US | 452 (100.0) | 836 (87.4) | 113 (98.3) | 44 (84.6) | 15 (93.8) | 100 (81.3) | 1560 (91.0) | |
| Outside US | 0 (0.0) | 121 (12.6) | 2 (1.7) | 8 (15.4) | 1 (6.3) | 23 (18.7) | 155 (9.0) | |
| Insurance status, n (%) | <.0001 | |||||||
| US Private | 167 (36.9) | 586 (70.1) | 36 (31.9) | 30 (68.2) | 10 (66.7) | 41 (41.0) | 870 (55.8) | |
| US Medicaid | 186 (41.2) | 148 (17.7) | 48 (42.5) | 8 (18.2) | 2 (13.3) | 28 (28.0) | 420 (26.9) | |
| US Other | 60 (13.3) | 52 (6.2) | 21 (18.6) | 4 (9.1) | 2 (13.3) | 10 (10.0) | 149 (9.6) | |
| US, Unknown | 39 (8.6) | 50 (6.0) | 8 (7.1) | 2 (4.5) | 1 (6.7) | 21 (21.0) | 121 (7.8) | |
| Non-US | 0 | 121 | 2 | 8 | 1 | 23 | 155 | |
| Area-based median household income category based on quartiles‡, n (%) | <.0001 | |||||||
| US, ≤$50 000 | 131 (29.0) | 163 (19.5) | 55 (48.7) | 4 (9.1) | 3 (20.0) | 18 (18.0) | 374 (24.0) | |
| US, $50 001-$65 000 | 137 (30.3) | 250 (29.9) | 25 (22.1) | 8 (18.2) | 4 (26.7) | 28 (28.0) | 452 (29.0) | |
| US, $65 001-$85 000 | 107 (23.7) | 214 (25.6) | 13 (11.5) | 14 (31.8) | 5 (33.3) | 26 (26.0) | 379 (24.3) | |
| US, ≥$85 000 | 71 (15.7) | 203 (24.3) | 16 (14.2) | 18 (40.9) | 2 (13.3) | 25 (25.0) | 335 (21.5) | |
| US, Unknown | 6 (1.3) | 6 (0.7) | 4 (3.5) | 0 (0.0) | 1 (6.7) | 3 (3.0) | 20 (1.3) | |
| Non-US | 0 | 121 | 2 | 8 | 1 | 23 | 155 | |
| Characteristics . | Race/ethnicity grouping . | |||||||
|---|---|---|---|---|---|---|---|---|
| Hispanic of all races (N = 452) . | NH White (N = 957) . | NH Black (N = 115) . | NH Asian (N = 52) . | NH Other (N = 16) . | Other/Unknown (N = 123) . | Total (N = 1715) . | P value . | |
| Institution size (based on frontline trial enrollment)∗, n (%) | .001 | |||||||
| Institution size: ≤50 | 55 (12.2) | 183 (19.2) | 27 (23.5) | 9 (17.3) | 2 (12.5) | 20 (16.3) | 296 (17.3) | |
| Institution size: 51-100 | 138 (30.5) | 295 (30.9) | 32 (27.8) | 12 (23.1) | 9 (56.3) | 23 (18.7) | 509 (29.7) | |
| Institution size: 101-200 | 161 (35.6) | 329 (34.5) | 42 (36.5) | 19 (36.5) | 3 (18.8) | 57 (46.3) | 611 (35.7) | |
| Institution size: >200 | 98 (21.7) | 148 (15.5) | 14 (12.2) | 12 (23.1) | 2 (12.5) | 23 (18.7) | 297 (17.3) | |
| Missing | 0 | 2 | 0 | 0 | 0 | 0 | 2 | |
| Treatment site location†, n (%) | <.0001 | |||||||
| US | 452 (100.0) | 836 (87.4) | 113 (98.3) | 44 (84.6) | 15 (93.8) | 100 (81.3) | 1560 (91.0) | |
| Outside US | 0 (0.0) | 121 (12.6) | 2 (1.7) | 8 (15.4) | 1 (6.3) | 23 (18.7) | 155 (9.0) | |
| Insurance status, n (%) | <.0001 | |||||||
| US Private | 167 (36.9) | 586 (70.1) | 36 (31.9) | 30 (68.2) | 10 (66.7) | 41 (41.0) | 870 (55.8) | |
| US Medicaid | 186 (41.2) | 148 (17.7) | 48 (42.5) | 8 (18.2) | 2 (13.3) | 28 (28.0) | 420 (26.9) | |
| US Other | 60 (13.3) | 52 (6.2) | 21 (18.6) | 4 (9.1) | 2 (13.3) | 10 (10.0) | 149 (9.6) | |
| US, Unknown | 39 (8.6) | 50 (6.0) | 8 (7.1) | 2 (4.5) | 1 (6.7) | 21 (21.0) | 121 (7.8) | |
| Non-US | 0 | 121 | 2 | 8 | 1 | 23 | 155 | |
| Area-based median household income category based on quartiles‡, n (%) | <.0001 | |||||||
| US, ≤$50 000 | 131 (29.0) | 163 (19.5) | 55 (48.7) | 4 (9.1) | 3 (20.0) | 18 (18.0) | 374 (24.0) | |
| US, $50 001-$65 000 | 137 (30.3) | 250 (29.9) | 25 (22.1) | 8 (18.2) | 4 (26.7) | 28 (28.0) | 452 (29.0) | |
| US, $65 001-$85 000 | 107 (23.7) | 214 (25.6) | 13 (11.5) | 14 (31.8) | 5 (33.3) | 26 (26.0) | 379 (24.3) | |
| US, ≥$85 000 | 71 (15.7) | 203 (24.3) | 16 (14.2) | 18 (40.9) | 2 (13.3) | 25 (25.0) | 335 (21.5) | |
| US, Unknown | 6 (1.3) | 6 (0.7) | 4 (3.5) | 0 (0.0) | 1 (6.7) | 3 (3.0) | 20 (1.3) | |
| Non-US | 0 | 121 | 2 | 8 | 1 | 23 | 155 | |
Bold values indicate P < .05.
Institution size based on number of enrollments from each institution (out of the 16 115 total enrollments) in the 12 frontline COG trials.
Non-US countries included Australia, Canada, New Zealand, and Switzerland.
Area-based median household income based on ZIP code for US patients only.